Philip Stevens

Philip Stevens is director of Geneva Network, a UK-based research organisation that focuses on innovation and trade policy.

Articles

Trade

Tariffs are hurting patients – and hampering the fight against Covid

While researchers in universities and private-sector laboratories work round-the-clock for new treatments and vaccines for Covid-19, physicians rely on a broad cabinet of older medicines to help patients through their darkest hour. Unprecedented demand caused by hospitals stockpiling basic medicines such as antibiotics, painkillers, sedatives, and corticosteroids has caused global shortages and surging prices. India’s […]

Economics

The OECD should think again on Colombian membership

In the mid 1990s Colombia was a war-stricken, pariah state plagued by narcotics gangs, Marxist rebels and right-wing paramilitary death squads. Today, thanks to years of market-friendly reforms, the country is on the cusp of acceding to the OECD, the elite club of wealthy, liberal democracies. Joining the OECD will bring great benefits to Colombia. […]

Ownership

Keep Colombia open for business

The transformation of Colombia’s economy over the past few years has been, in a word, remarkable. Outward-looking policies have helped to attract foreign business and investment, creating more jobs and raising wages for Colombians. Unfortunately, recent events in the health sector represent a real threat to continued economic progress. Since the early 2000s, Colombia has […]

Trade

Turkey’s free trade opportunity

Under Deputy Prime Minister Mehmet Şimşek, Turkey’s new government is pushing hard to reenergize free trade relationships with the EU and the US. The prize is deeper economic integration that will support its transformation into a modern economy and its escape from the middle-income trap in which it currently languishes. Turkey’s top priority is to […]

Ownership

A dose of reality on drug patents

Debates on how to improve healthcare in developing countries often start from the same premise: patents can potentially raise drug prices, so they should be abolished for better public health. In the early 2000s this argument drove the campaign against patents on HIV drugs in South Africa. This month, it anchors new NGO campaigns against […]

THE CAPITALIST

FOLLOW US

© 2026 CapX